ADVERTISEMENT
Log in here to read the desired article.
ADVERTISEMENT
This author has not written his bio yet.
But we are proud to say that Georg Kääb contributed 79 entries already.
Bayer can report a success in stroke treatment, even though an earlier study with the same compound had been discontinued due to limited benefit. The approach of inhibiting factor XIa represents a first-in-class example from Leverkusen. Whether the data will be sufficient for regulatory approval remains to be seen.
Novartis increased its annual profit in 2025 to USD 17.4 billion and raised its dividend. Towards the end of the year, however, growth weakened markedly, weighed down by copycat products. The group has therefore issued a cautious outlook for 2026. The CEO’s high, bonus-driven remuneration has sparked debate.
Pentixapharm Holding AG published new clinical Phase II data on its radiodiagnostic agent [68Ga]Ga-Pentixafor in early February. As the Berlin-based company reported, the results published in the Journal of Nuclear Medicine confirm the potential of Pentixafor PET/CT as a non-invasive alternative to adrenal venous sampling (AVS) for the subtyping of primary aldosteronism.
The Göttingen-based life science group Sartorius AG closed the 2025 financial year, based on preliminary figures, with a marked increase in revenue and earnings. Group sales grew by 7.6% at constant exchange rates to around EUR 3.54 billion, while the operating EBITDA margin rose by 1.7 percentage points to 29.7%.
CDMOs are currently setting the agenda across the industry. Alongside peers such as Vetter, Lonza has now delivered a clear statement of intent: strong results, sharper focus and an even more determined commitment to its core business. But the stronger investment strategy internationally frightens Switzerland – at least some analysts.
With an initial investment of around €480 million, Ravensburg-based Vetter Pharma has now fleshed out its plans to expand operations in Saarlouis, Saarland. The former automotive site is to be redeveloped by 2031 and is expected to employ up to 2,000 people in contract development and manufacturing.
Positive signals from a partnership with Takeda are allowing Heidelberg Pharma to push the setback from a milestone payment not received as planned from Telix somewhat into the background. Nevertheless, the company has been strongly shaken and is now hoping for calmer waters in order to drive its clinical development forward with greater focus.
Roche made a clear statement in 2025. The Basel-based group increased sales by 7% at constant exchange rates to CHF 61.5bn (€67bn) and lifted core operating profit by as much as 13%. For many observers, this represents far more than just a solid set of annual results.
Boehringer Ingelheim is continuing its international shopping tour for innovative drug candidates – and once again ends up in China. The German pharmaceutical group has entered into a licensing and development partnership with Shanghai-based Simcere Pharmaceutical Group to advance a novel bispecific antibody for the treatment of inflammatory bowel disease (IBD).
Dresden-based experts in sequence-precise gene repair, Seamless Therapeutics, have secured a heavyweight partner. The company has entered into a global research collaboration with the world’s largest pharmaceutical company by market cap, Eli Lilly, to apply its technology platform of specific recombinases to the development of gene therapies for hearing loss. For Seamless, the collaboration could generate total funding of up to USD 1.1 billion if milestones are successfully achieved.